New Jersey-based AACE Pharmaceuticals has been slammed in an FDA warning letter citing significant violations by its contract ...

COVID-19 tweets from November 2020 have come back to haunt Pfizer once again. | COVID-19 tweets from November 2020 have come ...

A month after the FDA lifted its clinical hold on GSK’s vaginal yeast infection drug Brexafemme (ibrexafungerp), the ...

While the Trump administration’s threat of pharmaceutical import tariffs and most favored nation (MFN) drug pricing has ...

Alnylam Pharmaceuticals has put its dancing shoes on to raise awareness of the experience of living with acute hepatic ...

Novartis’ $1.7 billion Regulus Therapeutics buyout last month came after a hard-fought battle in which the Swiss pharma and ...

After a poor showing of its COVID med vilobelimab in a rare skin disorder trial, German drugmaker InflaRx is going back to ...

AbbVie’s Allergan aesthetics unit is tightening up its workforce with 202 layoffs. | The layoffs at Allergan's Irvine, ...

After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers ...

Just a week after the FDA updated its stance on new COVID-19 | The CDC's recommended immunization schedule no longer includes ...

Following a string of vaccine expansion projects last year, Sanofi is eyeing a new path to potentially grow the reach of its ...

After meeting the mark alongside Keytruda in PD-L1-positive breast cancer earlier this year, Gilead Sciences' antibody-drug ...